import type { CompetitorRecord } from './competitor-database';

export const SPECIALTY_COMPETITORS_1: CompetitorRecord[] = [
  // ── Idiopathic Pulmonary Fibrosis (IPF) ──────────────────────────────────
  {
    asset_name: 'Ofev',
    generic_name: 'nintedanib',
    company: 'Boehringer Ingelheim',
    indication: 'Idiopathic Pulmonary Fibrosis',
    indication_specifics: 'Treatment of IPF in adult patients',
    mechanism: 'Triple angiokinase inhibitor (VEGFR, FGFR, PDGFR)',
    mechanism_category: 'kinase_inhibitor',
    molecular_target: 'VEGFR/FGFR/PDGFR',
    phase: 'Approved',
    primary_endpoint: 'Annual rate of decline in FVC',
    key_data: 'INPULSIS trials: Reduced annual FVC decline by ~50% vs placebo',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: ['Broad ILD label including SSc-ILD', 'Well-established safety profile'],
    weaknesses: ['GI side effects (diarrhea)', 'Does not improve lung function'],
    source: 'FDA label; INPULSIS trials; BI pipeline 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Esbriet',
    generic_name: 'pirfenidone',
    company: 'Genentech (Roche)',
    indication: 'Idiopathic Pulmonary Fibrosis',
    indication_specifics: 'Treatment of IPF in adult patients',
    mechanism: 'Anti-fibrotic (TGF-β modulator)',
    mechanism_category: 'anti_fibrotic',
    molecular_target: 'TGF-β',
    phase: 'Approved',
    primary_endpoint: 'Change in FVC',
    key_data: 'ASCEND: Reduced proportion of patients with ≥10% FVC decline or death',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: ['First approved anti-fibrotic for IPF', 'Oral formulation'],
    weaknesses: ['Photosensitivity', 'GI side effects', 'Generic competition'],
    source: 'FDA label; ASCEND trial; Roche 2024 annual report',
    last_updated: '2025-01-15',
  },

  // ── Systemic Lupus Erythematosus (SLE) ────────────────────────────────────
  {
    asset_name: 'Benlysta',
    generic_name: 'belimumab',
    company: 'GSK',
    indication: 'Systemic Lupus Erythematosus',
    indication_specifics: 'Active, autoantibody-positive SLE receiving standard therapy',
    mechanism: 'BLyS inhibitor (anti-BAFF)',
    mechanism_category: 'b_cell_modulator',
    molecular_target: 'BLyS/BAFF',
    phase: 'Approved',
    primary_endpoint: 'SRI-4 response rate',
    key_data: 'BLISS trials: Higher SRI-4 response at 52 weeks vs placebo',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['First biologic approved for SLE', 'Also approved for lupus nephritis', 'IV and SC formulations'],
    weaknesses: ['Modest efficacy in severe disease', 'Slow onset of action'],
    source: 'FDA label; BLISS trials; GSK 2024 annual report',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Saphnelo',
    generic_name: 'anifrolumab',
    company: 'AstraZeneca',
    indication: 'Systemic Lupus Erythematosus',
    indication_specifics: 'Moderate-to-severe SLE receiving standard therapy',
    mechanism: 'Type I interferon receptor antagonist',
    mechanism_category: 'interferon_modulator',
    molecular_target: 'IFNAR1',
    phase: 'Approved',
    primary_endpoint: 'BICLA response rate',
    key_data: 'TULIP-2: BICLA response 47.8% vs 31.5% placebo at week 52',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['Novel mechanism', 'Significant skin improvement', 'Steroid-sparing effect'],
    weaknesses: ['Herpes zoster risk', 'Less effective in high IFN-low patients'],
    source: 'FDA label; TULIP trials; AZ pipeline 2024',
    last_updated: '2025-01-15',
  },

  // ── Atopic Dermatitis ─────────────────────────────────────────────────────
  {
    asset_name: 'Dupixent',
    generic_name: 'dupilumab',
    company: 'Regeneron / Sanofi',
    indication: 'Atopic Dermatitis',
    indication_specifics: 'Moderate-to-severe atopic dermatitis in adults and children ≥6 months',
    mechanism: 'IL-4/IL-13 inhibitor',
    mechanism_category: 'interleukin_inhibitor',
    molecular_target: 'IL-4Rα',
    phase: 'Approved',
    primary_endpoint: 'IGA 0/1 and EASI-75',
    key_data: 'SOLO/CAFÉ: IGA 0/1 in 36-38% vs 8-10% placebo at week 16',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['$13B+ revenue franchise', 'Broadest label (AD, asthma, CRSwNP, EoE, COPD)', 'Strong safety profile'],
    weaknesses: ['Injection-site reactions', 'Conjunctivitis AE', 'Premium pricing pressure'],
    source: 'FDA label; SOLO trials; Regeneron 10-K 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Rinvoq',
    generic_name: 'upadacitinib',
    company: 'AbbVie',
    indication: 'Atopic Dermatitis',
    indication_specifics: 'Moderate-to-severe AD in adults and adolescents ≥12 years',
    mechanism: 'JAK1 selective inhibitor',
    mechanism_category: 'jak_inhibitor',
    molecular_target: 'JAK1',
    phase: 'Approved',
    primary_endpoint: 'EASI-75 and vIGA-AD 0/1',
    key_data: 'Measure Up 1/2: EASI-75 in 70% (30mg) vs 16% placebo at week 16',
    line_of_therapy: '2L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Oral formulation', 'Rapid onset', 'Superior efficacy vs Dupixent in head-to-head'],
    weaknesses: ['JAK class boxed warning', 'MACE/VTE safety monitoring', 'Step therapy requirements'],
    source: 'FDA label; Measure Up trials; AbbVie 10-K 2024',
    last_updated: '2025-01-15',
  },
];
